Australia’s medical cannabis market is shrinking for the first time since legalization in 2016. The Penington Institute reports a 28.5 percent sales decline in the second half of 2025 compared to the same period the previous year. The trigger: a major intervention by Australia’s Therapeutic Goods Administration (TGA) against aggressive advertising and click-prescription practices. The outcome offers a cautionary tale for every European market currently debating telehealth prescriptions and mail-order pharmacies—particularly Germany.
📑 Inhaltsverzeichnis
The Raw Numbers from the Penington Institute
In the second half of 2024, 3.72 million units of medical cannabis changed hands in Australia. One year later, in H2 2025, that figure dropped to just 2.65 million units. That’s a decline of 28.5 percent—the first market reversal since Australia approved medical cannabis in 2016, catapulting the country into one of the world’s largest patient markets. The Penington Institute, a public health research organization based in Melbourne, compiled these figures from TGA prescription data.
The collapse strikes a market that grew consistently in double digits in prior years. Between 2020 and 2023, Australia’s patient base multiplied annually, driven by a wave of private telemedical providers and low-barrier online consultations. Now, these exact structures are coming under regulatory scrutiny.
What the TGA Is Actually Enforcing
Starting in 2025, the Therapeutic Goods Administration implemented a series of compliance measures. Six cannabis companies, two private individuals, and over 50 physicians came under investigation. Allegations: unlawful advertising, misleading patient outreach, and insufficient diligence in prescribing practices. The TGA itself stated that high-volume clinics prioritized profit over patient care, evidenced in practice by extremely brief consultations. In some cases, fewer than ten minutes elapsed between initial patient contact and prescription issuance.
The Penington Institute notes that the TGA had already warned against these practices in 2023. At that time, enforcement remained limited. With the tightening in 2025, the picture changes dramatically. Advertising bans for prescription cannabis products are enforced more strictly, clinics must maintain consultation protocols, and prescription data is analyzed more closely. The result: providers withdraw from the market or scale back operations.
Parallels to the German Mail-Order Debate
Australia’s regulatory actions have direct bearing on Germany’s ongoing debate over planned amendments to the Medical Cannabis Act. The Federal Ministry of Health wants to ban mail-order distribution of cannabis flower and restrict telemedical consultations. Pharmacy associations, the German Cannabis Patient Association, and several patient organizations warn of service disruptions in rural regions and among patients with limited mobility. Australia demonstrates the flip side: where telemedical and online prescription markets grow unregulated, structures emerge that are extremely costly to correct later.
The Penington Institute cautions against blanket enforcement, however. An overly strict crackdown endangers access for patients who depend on cannabis therapy. This balance is precisely the question being debated in the Bundestag and German pharmacy chambers. Those following the German discussion will find useful comparative data on DACH-wide provision in our article on Canada’s share of the German medical cannabis market.
How the Correction Changes Market Structure
Three effects are visible in the Australian data. First, the provider market is consolidating. Smaller telehealth clinics shut down or get acquired. Second, the share of physicians operating independent practices with longer treatment histories is rising. Third, product shares are shifting: flower is losing market share to oils and standardized extracts, since these are simpler to document in prescriptions. The market isn’t just shrinking—it’s restructuring.
A fourth effect carries greater social weight. Patient advocacy groups in Australia report that many care pathways have become longer and more expensive. Patients previously served through telehealth clinics must now find general practitioners familiar with medical cannabis. In sparsely populated regions, this isn’t guaranteed. This shift echoes concerns voiced by German patient organizations like the German Cannabis Patient Association in their response to the draft amendment. Our Cannabis International Guide 2026 provides a global overview of medical cannabis markets.
Frequently Asked Questions
How large was the decline in Australia’s medical cannabis market?
In the second half of 2025, 2.65 million units were dispensed, down from 3.72 million in the prior year period. This represents a decline of 28.5 percent. Data comes from the Penington Institute based on TGA prescription statistics.
What caused the market collapse?
Australia’s Therapeutic Goods Administration tightened enforcement in 2025 against unlawful advertising and telehealth clinics conducting very brief consultations. Six cannabis companies, two private individuals, and over 50 physicians faced regulatory action. Providers withdrew from the market or reduced operations.
What role do telehealth clinics play in Australia?
Low-barrier online consultations drove rapid growth in Australia’s medical cannabis market between 2020 and 2023. With tightened enforcement in 2025, these exact structures face criticism. The TGA views many cases as prioritizing profit over patient care, with consultations under ten minutes deemed insufficient.
What parallels exist with the German market?
Germany’s Federal Ministry of Health is planning a mail-order ban for cannabis flower and telemedical restrictions. Australia demonstrates how a booming market, after inadequate initial regulation, undergoes correction. Germany’s debate attempts to encode this corrective course directly into legislation.
Does the crackdown endanger patient access?
The Penington Institute warns of exactly this risk. Patient advocates report longer and costlier care pathways as many telehealth providers exit. German patient organizations like the German Cannabis Patient Association and pharmacists voice similar concerns regarding the planned Medical Cannabis Act update.
Sources: Penington Institute (Melbourne), Therapeutic Goods Administration (TGA), Business of Cannabis (May 2026), German Cannabis Patient Association statement on Medical Cannabis Act draft.
Related Articles
- Cannabis Imports Decline for First Time in Two Years: 50.5 Tons in Q1 2026
- JAMA Study 2026: Why Older Adults Choose Cannabis Over Medications
- Cannabis Fair São Paulo 2026: Brazil Reaches 873,000 Patients, Closing Gap with Germany
- End of Flower on Insurance Plans? Finance Commission Calls for End to Public Coverage
Sollte Deutschland den Versandhandel mit Cannabisblüten verbieten?
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
